8-K

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549


                                    FORM 8-K


                                 CURRENT REPORT
     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

       Date of Report (Date of earliest event reported): December 6, 2004

                                      WYETH
             (Exact name of registrant as specified in its charter)


      Delaware                        1-1225                    13-2526821
(State or other jurisdiction       (Commission File            (IRS Employer
of incorporation)                   Number)                 Identification No.)




Five Giralda Farms, Madison, New Jersey                           07940
(Address of Principal Executive Offices)                       (Zip Code)

        Registrant's telephone number, including area code:  973-660-5000



                                 Not Applicable
          (Former name or former address, if changed since last report)

     Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

     |_| Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)

     |_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)

     |_| Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))

     |_| Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))







Item 8.01. Other Events.

The United Kingdom's Medicine and Healthcare products Regulatory Agency ("MHRA")
has informed Wyeth that it is imposing interim product labeling changes
for Wyeth's EFEXOR and EFEXOR XL products in the United Kingdom. The MHRA has
indicated that the interim labeling for these products in the United Kingdom
will state that: initiation of treatment should be restricted to specialist care
with starting doses limited to 75mg; the products are indicated for moderate to
severe patients; a baseline ECG is recommended for new patients; and the
products are contraindicated in patients with preexisting cardiovascular
disease. Additional information is available on the MHRA's Internet website at
www.mhra.gov.uk.

Wyeth intends to challenge the MHRA's action. Wyeth also will be communicating
with regulatory bodies worldwide regarding these matters. Wyeth's press release
responding to the MHRA's action is attached hereto as Exhibit 99 and
incorporated into this Item 8.01 by reference.

Wyeth's sales of EFEXOR and EFEXOR XL in the United Kingdom were approximately
$132 million in 2003 and $128 million for the first nine months of 2004. The
Company believes it is premature to assess the impact of the MHRA's action on
sales of its EFEXOR / EFFEXOR brand, although the impact could be material in
the United Kingdom and possibly in the balance of the world. The impact will
depend upon a number of risks and uncertainties, including possible
disagreements regarding the interpretation of the relevant medical and
scientific data, the reaction of the medical community and patients to the
MHRA's action and Wyeth's response, the outcome of Wyeth's challenge, any
actions taken by regulatory agencies outside the United Kingdom, any adverse
political response or media coverage, any related litigation such as product
liability suits, and other risks and uncertainties, including those detailed
from time to time in the Company's periodic reports, including current reports
on Form 8-K, quarterly reports on Form 10-Q and the annual report on Form 10-K,
filed with the Securities and Exchange Commission.


Item 9.01. Financial Statements and Exhibits

(c)  Exhibits.


Exhibit No. Description

 (99)       Wyeth Press Release, dated December 6, 2004.









                                   SIGNATURES


     Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


Date:    December 6, 2004       WYETH

                                 By:       /s/ Lawrence V. Stein
                                 ---------------------------------------------
                                 Name:    Lawrence V. Stein
                                 Title:   Senior Vice President and
                                          General Counsel









                                  Exhibit Index


Exhibit No. Description

 (99)       Wyeth Press Release, dated December 6, 2004.

EX-99

[WYETH LOGO]                                       N E W S  R E L E A S E


Media Contacts:                             Investor Contact:
Gill Markham                                Justin Victoria
Wyeth UK                                    Wyeth
44 1628 604 377                             (973) 660-5340

Douglas Petkus
Wyeth Pharmaceuticals
(484) 865-5140

Natalie de Vane
Wyeth Pharmaceuticals
(484) 865-5139


               WYETH AFFIRMS THE SAFETY AND EFFICACY OF EFEXOR AND
                     EFEXOR XL IN RESPONSE TO MHRA ACTIONS
                              ON SSRI's AND EFEXOR

             --MHRA Proposed Changes to EFEXOR Label Not Consistent
                           with Scientific Evidence--


         Taplow, U.K., December 6, 2004 --Wyeth Pharmaceuticals, a division of
Wyeth (NYSE:WYE), today affirms the safety and efficacy of EFEXOR(R)
(venlafaxine HCl) and EFEXOR XL(R) (venlafaxine HCl sustained release),
(collectively EFEXOR), and disagrees with the United Kingdom's (UK) Medicine and
Healthcare Products Regulatory Agency's (MHRA) decision to require interim
measures that would restrict access to these treatments.

"Wyeth's most recent review of preclinical and clinical data, and 10 years of
post-marketing experience with more than 10 million patients, confirm the safety
and efficacy of EFEXOR for the treatment of depression and anxiety," says Gary
L. Stiles, M.D., Executive Vice President, Chief Medical Officer for Wyeth
Pharmaceuticals.

         The MHRA has required provisional labeling for EFEXOR in the UK that
will state that: initiation of treatment should be restricted to specialist care
with starting doses limited to 75mg; the products are indicated for moderate to
severe patients; a baseline ECG is recommended for new patients; and, the
products are contraindicated in patients with preexisting cardiovascular
disease. Additional information regarding the MHRA's action is available on its
Internet web site at www.mhra.gov.uk.

         The MHRA's provisional action stems from, among other factors, its view
that EFEXOR could be associated with disruption of the heart rhythm, and could
be associated with severe reactions following abrupt discontinuation.
Additionally, the Agency reviewed publications relying on data from the Office
of National Statistics (ONS). The ONS data suggest that EFEXOR is associated
with a rate of fatal overdose significantly higher than selective serotonin
reuptake inhibitors (SSRIs), but significantly lower than the rate associated
with tricyclic antidepressants (TCAs).

         Wyeth's analyses of the ONS report using the UK's General Practice
Research Database (GPRD) found that physicians prescribed EFEXOR to patients who
on average had more risk factors for suicide than patients who were prescribed
certain SSRIs. This is not unexpected since in clinical practice EFEXOR is
frequently used when other agents (SSRIs, TCAs) have been ineffective.
Specifically, prior to receiving EFEXOR, these patients had a higher incidence
of prior hospitalizations for depression, schizophrenia along with depression,
failure to respond to other antidepressants, and suicidal behavior in the
preceding year. The magnitude of these risk factors is strikingly similar to the
different rates of fatal overdose that were seen.

         Moreover, in data from clinical trials in which there were controls to
assure that patients were similar, EFEXOR was superior to placebo in reducing
suicidal thoughts and performed at least as well as comparator SSRIs. Thus it
appears most likely that the increased rate of fatal overdose observed with
EFEXOR actually reflects a differential risk of suicide attempt inherent to the
patients' conditions rather than a direct effect of EFEXOR itself.

         "These data do not establish a relationship between therapeutic doses
of EFEXOR and cardiac arrhythmias (disruptions of the heart rhythm) beyond what
is currently described in our labeling," says Dr. Stiles.

          Allison Jeynes-Ellis, M.D., Wyeth Medical Director, United Kingdom and
Republic of Ireland, adds, "The MHRA's conclusions fail to account for these
critical data. Restricting access to medication is not in the best interest of
patients, and is a backward step in the treatment of depression in this country.
In the UK, many of the nearly 300,000 EFEXOR patients have failed on one or more
other antidepressants. The MHRA's action may lead to the increased use of less
appropriate medications such as TCAs that have a long history of safety concerns
- - including a higher risk of fatal overdose, suicide, and disruptions of cardiac
rhythm at therapeutic doses."

         The MHRA has asked for new class labeling addressing suicide risk,
dosing and discontinuation. Wyeth finds these changes consistent with the
Company's recent labeling proposals made in the UK and is evaluating the
appropriateness of these changes in other parts of the world.

         While the MHRA has reaffirmed EFEXOR as an "important drug in treating
many patients with depressive illness," Wyeth finds that the provisional
labeling required by the MHRA will needlessly place restrictions on the future
use of EFEXOR by inappropriately defining broad cardiovascular contraindications
and by limiting initiation of EFEXOR therapy to specialist care.

         Wyeth will challenge the MHRA's action and has urged the agency to
accept the Company's previous recommendations for enhanced labeling, educational
initiatives, and new packaging aimed to help physicians and patients reduce the
risk of suicide and overdose. During the process, Wyeth will comply with the
MHRA interim measures in accordance with regulation 6A of the Medicines for
Human Use Regulations 1994. In addition, the Company intends to communicate with
regulatory bodies worldwide regarding this information.

BACKGROUND INFORMATION

Treatment of Depression in the UK
- ---------------------------------

         In the UK, the treatment of depression is most often initiated and
managed by General Practitioners in the primary care setting. Restricting
initiation of treatment with EFEXOR to specialist care will place an unnecessary
burden on specialists and could be detrimental to patients. According to the
Department of Health, in the first quarter of 2004, approximately 10,000 UK
mental health patients had to wait more than 17 weeks to see a psychiatrist.
This is concerning, as frequency and ease of access to a physician is considered
essential in efforts to prevent suicides in patients with significant
depression.

Discontinuation of Treatment
- ----------------------------

         Discontinuation of EFEXOR may cause withdrawal symptoms in some
patients. It has always been recommended that discontinuation of therapy be
gradual, as appropriately tapering the dose minimizes the risk of patients
developing symptoms. Patients should not discontinue therapy without consulting
with their prescribing physician.

About Venlafaxine in the United States
- --------------------------------------

         In the United States, venlafaxine is marketed as EFFEXOR(R)
(venlafaxine HCl) and EFFEXOR XR(R) (venlafaxine HCl sustained release). EFFEXOR
XR is indicated for the treatment of patients with major depressive disorder,
generalized anxiety, and social anxiety disorder. EFFEXOR/EFFEXOR XR is
contraindicated in patients taking monoamine oxidase inhibitors (MAOIs). Both
adult and pediatric patients taking antidepressants can experience worsening of
their depression and/or the emergence of suicidality. Patients should be
observed closely for clinical worsening and suicidality, especially at the
beginning of drug therapy, or at the time of increases or decreases in dose.

         Anxiety, agitation, panic attacks, insomnia, irritability, hostility,
impulsivity, akathisia, hypomania, and mania have been reported in patients
taking antidepressants. Discontinuation or modification of therapy should be
considered when symptoms are severe, abrupt in onset, or not part of presenting
symptoms.

         Treatment with venlafaxine is associated with sustained increases in
blood pressure (BP) in some patients. Regular BP monitoring is recommended.
Abrupt discontinuation or dose reduction has been associated with
discontinuation symptoms. Patients should be counseled on possible
discontinuation symptoms and monitored while discontinuing the drug; the dose
should be tapered gradually.

         The most common adverse events reported in EFFEXOR XR short-term
placebo-controlled depression trials and EFFEXOR XR short-term
placebo-controlled depression, generalized anxiety disorder (GAD), and/or social
anxiety disorder trials (incidence [greater than or equal to] 10% and [greater
than or equal to] 2x that of placebo) were anorexia, asthenia, constipation,
dizziness, dry mouth, ejaculation problems, impotence, insomnia, nausea,
nervousness, somnolence, and sweating.

         EFFEXOR XR was discovered and developed by Wyeth Pharmaceuticals, the
pharmaceutical division of Wyeth. The product is also marketed by Wyeth
Pharmaceuticals. The FDA approved the immediate-release formulation in 1993; the
extended-release (XR) formulation was approved in 1997. These medications are
available only by prescription.

About Wyeth Pharmaceuticals
- ---------------------------

         Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), has leading
products in the areas of women's health care, cardiovascular disease, central
nervous system, inflammation, transplantation, hemophilia, oncology, vaccines
and nutritional products. Wyeth is one of the world's largest research-driven
pharmaceutical and health care products companies.

         It is a leader in the discovery, development, manufacturing, and
marketing of pharmaceuticals, vaccines, biotechnology products, and
nonprescription medicines that improve the quality of life for people worldwide.

         The Company's major divisions include Wyeth Pharmaceuticals, Wyeth
Consumer Health Care, and Fort Dodge Animal Health.

                                     ######

The statements in this press release that are not historical facts are
forward-looking statements based on current expectations of future events. These
statements should be evaluated together with the many risks and uncertainties
that affect Wyeth's business, including those detailed from time to time in
Wyeth's periodic reports, including current reports on Form 8-K, quarterly
reports on Form 10-Q and the annual report on Form 10-K, filed with the
Securities and Exchange Commission. Actual results may vary materially from the
forward-looking statements as a result of these risks and uncertainties. Wyeth
assumes no obligation to publicly update any forward-looking statements, whether
as a result of new information, future events or otherwise.

Investors are directed for more information to Wyeth's Current Report on Form
8-K regarding the MHRA's action, which will be filed today with the United
States Securities and Exchange Commission and will be available on Wyeth's web
site at www.wyeth.com.
        -------------